Format

Send to

Choose Destination
Epigenomics. 2018 Sep;10(9):1189-1199. doi: 10.2217/epi-2018-0017. Epub 2018 Sep 5.

Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.

Peng D1,2,3,4,5, Ge G2,6, Xu Z2,6, Ma Q2, Shi Y2, Zhou Y2, Gong Y1,3,4,5, Xiong G1,3,4,5, Zhang C1,3,4,5, He S1,3,4,5, He Z1,3,4,5, Li X1,3,4,5, Ci W2,6, Zhou L1,3,4,5.

Author information

1
Department of Urology, Peking University First Hospital, Beijing, PR China.
2
Key Laboratory of Genomics & Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, PR China.
3
Institute of Urology, Peking University, Beijing, PR China.
4
National Urological Cancer Center, Beijing, PR China.
5
Urogenital Diseases (Male) Molecular Diagnosis & Treatment Centre, Peking University, Beijing, PR China.
6
University of Chinese Academy of Sciences, Beijing 100049, PR China.

Abstract

AIM:

We intended to construct DNA methylation-based models for the diagnosis and prognosis of three common urological cancers including prostate adenocarcinoma, renal clear cell carcinoma and bladder urothelial carcinoma.

MATERIALS & METHODS:

TotalĀ 450K methylation array data from the cancer genome atlas and gene expression omnibus datasets were downloaded. Moderated t-statistics and least absolute shrinkage and selection operator method were used to build diagnosis and prognosis models.

RESULTS:

Our diagnostic panels including 128 CpG sites had high sensitivity and accuracy in distinguishing samples and could identify lymphatic metastases in prostate adenocarcinoma patients. The prognostic models with 19 CpG sites for renal clear cell carcinoma and 21 CpG sites for bladder urothelial carcinoma were able to distinguish high- and low-risk patients and improve the predictive ability of the tumor node metastasis staging system.

CONCLUSION:

DNA methylation may afford reliable biomarkers in the diagnosis and prognosis of common urological cancers.

KEYWORDS:

DNA methylation; TCGA; biomarker; bladder cancer; prostate cancer; renal cancer

PMID:
30182734
DOI:
10.2217/epi-2018-0017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center